Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

could also drive substantial gains if it steals a march over Novo's amycretin, which achieved 24% placebo adjusted weight loss in a recent study, or Structure's ACCG-2671, which is frankly a much ...

Structure Therapeutics’ oral GLP-1aleniglipron is also in the running, with a Phase II readout expected later this year. Novo’s oral obesity drug, meanwhile, is in earlier stages. Last fall, the ...

Data on the subcutaneous version of amycretin is due next year, and Novo Nordisk also presented early data on another oral therapy, CBR1 inverse agonist monlunabant (INV-202), which showed a 3% ...

Despite Novo Nordisk's stock decline ... including oral semaglutide and Amycretin, remains highly competitive. The partnership with Hims & Hers mitigates legal risks and boosts distribution ...

Novo Nordisk said it is now planning to advance both subcutaneous and oral formulations of amycretin into additional clinical trials. The new data follows another study that showed the ...

On Wednesday, BofA Securities revised its price target for Novo Nordisk (NOVOB ... Finally, the regulatory process for Amycretin is ongoing, with an FDA decision expected in the coming months.

Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But that’s reflective of the tough times the Danish maker of Ozempic and ...